WO2004055211A3 - Compositions et methodes pour la detection et le traitement de pathologies neurodegénératives - Google Patents

Compositions et methodes pour la detection et le traitement de pathologies neurodegénératives Download PDF

Info

Publication number
WO2004055211A3
WO2004055211A3 PCT/FR2003/003700 FR0303700W WO2004055211A3 WO 2004055211 A3 WO2004055211 A3 WO 2004055211A3 FR 0303700 W FR0303700 W FR 0303700W WO 2004055211 A3 WO2004055211 A3 WO 2004055211A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
detecting
neurodegenerative pathologies
concerns
Prior art date
Application number
PCT/FR2003/003700
Other languages
English (en)
Other versions
WO2004055211A2 (fr
Inventor
Fabien Schweighoffer
Annelies Resink
Laurent Desire
Original Assignee
Exonhit Therapeutics Sa
Fabien Schweighoffer
Annelies Resink
Laurent Desire
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonhit Therapeutics Sa, Fabien Schweighoffer, Annelies Resink, Laurent Desire filed Critical Exonhit Therapeutics Sa
Priority to AU2003300589A priority Critical patent/AU2003300589A1/en
Publication of WO2004055211A2 publication Critical patent/WO2004055211A2/fr
Publication of WO2004055211A3 publication Critical patent/WO2004055211A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et méthodes pour la détection et le traitement de pathologies neurodegénératives. Elle décrit notamment l'identification de nouvelles voies métaboliques et de nouvelles cibles moléculaires impliquées dans le développement de pathologies neurodégénératives, ainsi que des approches diagnostiques et thérapeutiques basées sur une modulation de ces voies ou de l'activité de ces cibles. L'invention décrit notamment la présence, chez des patients atteints, d'altérations moléculaires dans la voie de synthèse des prostaglandines PGD2 et permet le développement de stratégies thérapeutiques et diagnostiques efficaces et spécifiques. L'invention concerne également des méthodes, outils, constructions et compositions adaptées à la mise en oeuvre de ces stratégies.
PCT/FR2003/003700 2002-12-13 2003-12-12 Compositions et methodes pour la detection et le traitement de pathologies neurodegénératives WO2004055211A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003300589A AU2003300589A1 (en) 2002-12-13 2003-12-12 Compositions and methods for detecting and treating neurodegenerative pathologies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215859A FR2848573B1 (fr) 2002-12-13 2002-12-13 Compositions et methodes pour la detection et le traitement de pathologies neurodegeneratives
FR02/15859 2002-12-13

Publications (2)

Publication Number Publication Date
WO2004055211A2 WO2004055211A2 (fr) 2004-07-01
WO2004055211A3 true WO2004055211A3 (fr) 2004-09-30

Family

ID=32338791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/003700 WO2004055211A2 (fr) 2002-12-13 2003-12-12 Compositions et methodes pour la detection et le traitement de pathologies neurodegénératives

Country Status (3)

Country Link
AU (1) AU2003300589A1 (fr)
FR (1) FR2848573B1 (fr)
WO (1) WO2004055211A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2929292A1 (fr) * 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040162A1 (fr) * 1995-06-07 1996-12-19 East Carolina University Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens
WO1999046403A1 (fr) * 1998-03-11 1999-09-16 Exonhit Therapeutics S.A. Criblage differentiel qualitatif
WO2001016312A2 (fr) * 1999-08-31 2001-03-08 Ribozyme Pharmaceuticals, Inc. Modulateurs d'expression genetique a base d'acide nucleique
WO2002010449A2 (fr) * 2000-07-28 2002-02-07 Compugen Inc. Bibliotheque d'oligonucleotides destinee a detecter des transcrits d'arn et des variantes d'epissure qui garnissent un transcriptome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040162A1 (fr) * 1995-06-07 1996-12-19 East Carolina University Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens
WO1999046403A1 (fr) * 1998-03-11 1999-09-16 Exonhit Therapeutics S.A. Criblage differentiel qualitatif
WO2001016312A2 (fr) * 1999-08-31 2001-03-08 Ribozyme Pharmaceuticals, Inc. Modulateurs d'expression genetique a base d'acide nucleique
WO2002010449A2 (fr) * 2000-07-28 2002-02-07 Compugen Inc. Bibliotheque d'oligonucleotides destinee a detecter des transcrits d'arn et des variantes d'epissure qui garnissent un transcriptome

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MCSWIGGEN, JAMES ET AL: "Nucleic acid-based ribozyme and DNAzyme modulators of gene expression", XP002287672, retrieved from STN Database accession no. 135:16022 *
DATABASE EMBL [online] 15 July 2002 (2002-07-15), SHOSHAN A. ET AL., XP002285626, retrieved from EBI Database accession no. ABN36779 *
DATABASE EMBL [online] 22 February 2002 (2002-02-22), MELTON D. ET AL.: "Endocrine pancreas consortium", XP002254709, retrieved from EBI Database accession no. BM511231 *
DATABASE EMBL [online] 27 November 2000 (2000-11-27), XP002285625, retrieved from EBI Database accession no. BF340455 *
DATABASE EMBL [online] 8 November 2002 (2002-11-08), WISTOW G. ET AL.: "Expressed sequence tag analysis of human RPE/choroid for the NEIbank project: over 6000 non-redundant trnascripts, novel genes and splice variants", XP002254710, retrieved from EBI Database accession no. CA394063 *
DATABASE PUBMED [online] 24 June 2003 (2003-06-24), XP002252056, Database accession no. NM_000954 *
IWAMOTO N ET AL: "THE FORMATION OF PROSTAGLANDINS IN THE POSTMORTEM CEREBRAL CORTEX OF ALZHEIMER-TYPE DEMENTIA PATIENTS", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN, DE, vol. 236, no. 2, February 1989 (1989-02-01), pages 80 - 84, XP009015982, ISSN: 0340-5354 *
JAIN N K ET AL: "Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 133, no. 2, 18 July 2002 (2002-07-18), pages 369 - 376, XP001155058, ISSN: 0166-4328 *
REICHLE ALBRECHT ET AL: "Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in histiocytosis X, angiocentric T-cell lymphoma and Hodgkin's disease: Case reports from a on-going phase II study", BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), 43rd Annual Meeting of the American Society of Hematology, Part 2;Orlando, Florida, USA; December 07-11, 2001, pages 246b, XP009032579, ISSN: 0006-4971 *
SATOH K ET AL: "Expression of prostaglandin E synthase mRNA is induced in beta-amyloid treated rat astrocytes.", NEUROSCIENCE LETTERS. IRELAND 14 APR 2000, vol. 283, no. 3, 14 April 2000 (2000-04-14), pages 221 - 223, XP001154483, ISSN: 0304-3940 *
URYU SHIGEKO ET AL: "Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons.", BRAIN RESEARCH. NETHERLANDS 11 JAN 2002, vol. 924, no. 2, 11 January 2002 (2002-01-11), pages 229 - 236, XP002254290, ISSN: 0006-8993 *
WHITE D M ET AL: "Structure and chromosomal localization of the human gene for a brain form of prostaglandin D2 synthase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 267, no. 32, 15 November 1992 (1992-11-15), pages 23202 - 23208, XP002955768, ISSN: 0021-9258 *
WISTOW G. ET AL.: "Expressed sequence tag analysis of human RPE/choroid for the NEIbank project: over 6000 non-redundant transcripts, novel genes and splice variants", MOL. VIS., vol. 8, 2002, pages 205 - 220, XP002979786 *
YAGAMI T ET AL: "Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death.", BRITISH JOURNAL OF PHARMACOLOGY. ENGLAND OCT 2001, vol. 134, no. 3, October 2001 (2001-10-01), pages 673 - 681, XP002252055, ISSN: 0007-1188 *

Also Published As

Publication number Publication date
FR2848573A1 (fr) 2004-06-18
WO2004055211A2 (fr) 2004-07-01
AU2003300589A1 (en) 2004-07-09
FR2848573B1 (fr) 2005-04-08

Similar Documents

Publication Publication Date Title
WO2004037159A3 (fr) Composes, compositions et methodes permettant de moduler le metabolisme des graisses
WO2005082341A3 (fr) Agents non peptidyl a activite de type phsp20 et utilisations correspondantes
WO2005014035A3 (fr) Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
WO2003059251A3 (fr) Composes de ciblage d'anticorps
ATE524495T1 (de) Pd-1-spezifische substanz
WO2003089456A3 (fr) Inhibiteurs peptidiques de la proteine kinase c
AU2003271174A1 (en) Double specific antibodies substituting for functional protein
WO2005005599A3 (fr) Modulation de l'expression de la proteine c-reactive
NO20062663L (no) Nukleinsyre som spesifikt binder bioaktivt ghrelin
WO2003055917A3 (fr) Nouvelles methodes de diagnostic et de traitement de tumeurs
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
DK1515752T3 (da) ACE2-aktivering til behandling af hjerte-, lunge- og nyresygdomme og hypertension
WO2006028429A3 (fr) Peptide pour cibler l'antigene prostatique membranaire specifique
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
WO2006074450A3 (fr) Methodes et compositions permettant de detecter et de moduler les maladies et les troubles parodontaux
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2004076614A3 (fr) Sequences d'acide nucleique humaines issues de carcinomes de la prostate
WO2004027418A3 (fr) Utilisation de marqueurs moleculaires pour le profilage preclinique et clinique d'inhibiteurs d'enzymes possedant une activite d'histone-desacetylase
WO2003102185A3 (fr) Procedes et compositions pour traiter une neoplasie associee aux molecules d'acides nucleiques de a1 et a2 de hnrnp
WO2004055211A3 (fr) Compositions et methodes pour la detection et le traitement de pathologies neurodegénératives
WO2004070012A3 (fr) Molecules d'elimination de cellules et methodes d'utilisation associees
PL374550A1 (en) Il-17 like molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP